Boucle Sebastien, Bassit Leda, Ehteshami Maryam, Schinazi Raymond F
Laboratory of Biochemical Pharmacology, Department of Pediatrics, Center for AIDS Research, Emory University School of Medicine, 1760 Haygood Drive, Atlanta, GA 30322, USA.
Laboratory of Biochemical Pharmacology, Department of Pediatrics, Center for AIDS Research, Emory University School of Medicine, 1760 Haygood Drive, Atlanta, GA 30322, USA.
Clin Liver Dis. 2016 Nov;20(4):737-749. doi: 10.1016/j.cld.2016.07.001. Epub 2016 Aug 30.
Hepatitis B virus (HBV) causes significant morbidity and mortality worldwide. The majority of chronically infected individuals do not achieve a functional and complete cure. Treated persons who achieve a long-term sustained virologic response (undetectable HBV DNA), are still at high risk of developing morbidity and mortality from liver complications. This review focuses on novel, mechanistically diverse anti-HBV therapeutic strategies currently in development or in clinical evaluation, and highlights new combination strategies that may contribute to full elimination of HBV DNA and covalently closed circular DNA from the infected liver, leading to a complete cure of chronic hepatitis B.
乙型肝炎病毒（HBV）在全球范围内导致了严重的发病和死亡。大多数慢性感染者无法实现功能性和彻底治愈。实现长期持续病毒学应答（HBV DNA检测不到）的接受治疗者，仍面临因肝脏并发症而发病和死亡的高风险。本综述重点关注目前正在研发或处于临床评估阶段的新型、机制多样的抗HBV治疗策略，并强调可能有助于从感染肝脏中完全清除HBV DNA和共价闭合环状DNA，从而实现慢性乙型肝炎彻底治愈的新联合策略。
